# Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum

> **NCT04060550** · — · UNKNOWN · sponsor: **National Jewish Health** · enrollment: 36 (estimated)

## Conditions studied

- Atopic Dermatitis With a History of Eczema Herpeticum
- Atopic Dermatitis Without a History of Eczema Herpeticum
- Health Controls Without Atopy

## Interventions

- **BIOLOGICAL:** Xolair

## Key facts

- **NCT ID:** NCT04060550
- **Lead sponsor:** National Jewish Health
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-09
- **Primary completion:** 2021-07-31
- **Final completion:** 2021-07-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2021-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04060550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04060550, "Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04060550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*